1. 减值损失减少：2024财年计提商誉减值及其他无形资产减值亏损198.9 百万元及其他无形资产减值亏 损约人民币6.8 百万元，2025财年相关减值金额预计大幅下降。 2. 战略优化显效：城市布局方面，聚焦北京、上海、深圳等核心一线城市，加密智慧药房网络，提升运 营效率；商品策略方面，强化供应链能力，优化产品结构，提高高毛利品类占比。 3. 盈利转折关键：集团预计2025财年实现经调整净利润(非国际财务报告准则指标)不低于人民币5百万 元，相较2024财年约人民幣57.2 百万元之经调整净亏损明显改善，实现扭亏为盈。 叮当健康(09886.HK)发布盈利预警。根据初步评估，集团预计截至2025年12月31日止年度净亏损较2024 财年显著收窄80%。 公告显示，亏损大幅减少主要受惠于以下因素： （原标题：叮当健康发布预告：2025经调整净利润扭亏为盈，核心盈利时代开启） ...

经济观察网 基于公开信息，1药网（YI.US）在2026年有以下值得关注的事件： 行业政策与环境 根据国家发改委、市场监管总局和国家网信办联合发布的《互联网平台价格行为规则》，该规则计划于 2026年4月10日起正式实施，为期五年。新规针对互联网平台价格行为进行规范，包括禁止低于成本销 售、保护经营者自主定价权等，可能对医药电商行业的竞争环境产生影响。其他公开事件如财报发布或 公司特定动态，需以官方公告为准。 以上内容基于公开资料整理，不构成投资建议。 ...

2026.02. 14 本文字数：2911，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 药店进驻电商平台"赔本赚吆喝"，药企深陷"平台二选一"，线上"卖药"低于厂商成本价，"互联网+"服 务价格不透明、隐形收费……这些扰乱医药市场的价格乱象将迎来更强监管，平台企业或面临"大 考"。 13日，市场监管总局发布《互联网平台反垄断合规指引》，明确"全网最低价"等多个新型垄断风险行 为。同日，该局发布《医疗机构价格公示规定（征求意见稿）》，这是时隔24年该规定首次修订， 并首次将互联网医院纳入监管范围，对线上处方所涉及的药品价格公示提出了独立、详尽的要求，强 调线上线下主体的一致性。 "结合此次发布两个文件，后续医药价格与平台竞争监管将重点围绕合理定价边界、价格公示规范、 信息披露尺度、多部门监管分工四大核心，形成清晰合规框架。"北京中医药大学卫生健康法学教授 邓勇对第一财经表示。 他认为，整体来看，本轮监管既允许平台与医药机构基于成本差异合理定价，又严格划定禁止低价倾 销、禁止价格欺诈、禁止垄断、强制透明公示四条红线。在促进线上线下有序竞争的同时，保障患者 知情权与医保基金安全。 医药电商"补贴""促销"或迎更 ...

严格划定禁止低价倾销、禁止价格欺诈、禁止垄断、强制透明公示四条红线。 药店进驻电商平台"赔本赚吆喝"，药企深陷"平台二选一"，线上"卖药"低于厂商成本价，"互联网+"服 务价格不透明、隐形收费……这些扰乱医药市场的价格乱象将迎来更强监管，平台企业或面临"大考"。 13日，市场监管总局发布《互联网平台反垄断合规指引》，明确"全网最低价"等多个新型垄断风险行 为。同日，该局发布《医疗机构价格公示规定（征求意见稿）》，这是时隔24年该规定首次修订，并首 次将互联网医院纳入监管范围，对线上处方所涉及的药品价格公示提出了独立、详尽的要求，强调线上 线下主体的一致性。 "结合此次发布两个文件，后续医药价格与平台竞争监管将重点围绕合理定价边界、价格公示规范、信 息披露尺度、多部门监管分工四大核心，形成清晰合规框架。"北京中医药大学卫生健康法学教授邓勇 对第一财经表示。 他认为，整体来看，本轮监管既允许平台与医药机构基于成本差异合理定价，又严格划定禁止低价倾 销、禁止价格欺诈、禁止垄断、强制透明公示四条红线。在促进线上线下有序竞争的同时，保障患者知 情权与医保基金安全。 医药电商"补贴""促销"或迎更强监管 该指引称，平台经 ...

Investment Rating - The report assigns a "Buy" rating for Alibaba Health, with a target price of HKD 7.39 per share [7]. Core Insights - The main business of Alibaba Health is experiencing accelerated growth, driven by the online penetration of innovative drugs and the integration of AI technologies, which present new opportunities for the company [7]. - The self-operated revenue of Alibaba Health has significantly increased, accounting for nearly 90% of total revenue, with a year-on-year growth of 19% to RMB 14.38 billion [7]. - The company is also the largest online B2C healthcare product retail platform in China, benefiting from deep collaboration with the Alibaba Group [7]. Summary by Sections Medical E-commerce Tracking - The online pharmacy market share is rapidly increasing, with innovative drugs driving growth. The retail pharmacy share has risen to 31.5%, while online pharmacies have reached 5.3% [14][15]. - The demand for original research drugs is increasing, with a shift towards online channels due to convenience and service [15][16]. Alibaba Health - The self-operated business is the main driver of revenue growth, with a 99% year-on-year increase in self-operated SKUs to 1.61 million [7]. - The company is enhancing its advertising capabilities, which will contribute significantly to profitability [7]. - AI technologies are expected to empower the main business, with initiatives like the "Qianwen Super Agent" and the medical AI assistant "Hydrogen Ion" app being developed [7]. Profit Forecast and Valuation - Revenue forecasts for fiscal years 2026 and 2027 are RMB 34.594 billion and RMB 38.235 billion, respectively, with adjusted net profits of RMB 2.499 billion and RMB 3.026 billion [2][7].

Core Viewpoint - The company 1药网 (YI.US) has reported its Q3 2025 earnings, achieving Non-GAAP operating profit for three consecutive quarters and generating positive operating cash flow, with total revenue reaching 3 billion RMB [1][2]. Financial Performance - The total revenue for Q3 2025 is reported at 3 billion RMB, marking three consecutive quarters of Non-GAAP operating profit and achieving positive operating cash flow for the quarter [2]. Business Development - The company is accelerating its transition to a light-asset model and enhancing the application of AI technology, particularly in smart supply chain and digital order fulfillment center upgrades [3]. Future Outlook - Key upcoming events include the release of Q4 2025 and full-year financial reports, as well as the company's further execution of its AI transformation strategy. The pharmaceutical industry is expected to see gradual improvement in the operating environment in 2026, which may indirectly impact individual stocks. Specific event dates will be based on official company announcements [4].

股票近期走势 以上内容基于公开资料整理，不构成投资建议。 经济观察网1药网(YI.OQ)股价在2026年2月11日出现下跌，单日跌幅为5.26%，收盘价报7.57美元。根据 当日交易数据，该股开盘价为7.91美元，最高价7.91美元，最低价7.43美元，振幅达6.01%，成交量为 5,701股，成交金额为43,781美元，换手率为0.07%。 从市场表现看，当日1药网所属的美股医疗销售板块微涨0.47%，而美股大盘指数道琼斯和纳斯达克分 别下跌0.02%和0.04%，显示个股表现弱于板块及大盘。同期，A股医药电商板块(代码：02250004)下跌 0.59%，主力资金净流出约11.08亿元，反映医药电商领域整体承压。 ...

Group 1 - Southbound funds increased their holdings in Alibaba Health (00241.HK) by 4.238 million shares on February 6 [1] - Over the past 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 26.959 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, with a total net increase of 181 million shares [1] Group 2 - As of now, southbound funds hold 1.945 billion shares of Alibaba Health, accounting for 12.02% of the company's total issued ordinary shares [1] - Alibaba Health Information Technology Co., Ltd. provides industrial internet solutions for the medical and pharmaceutical industry and is Alibaba Group's flagship platform in the health sector [1] - The company primarily engages in the sales of pharmaceutical health products, operates a pharmaceutical e-commerce platform, and offers consumer medical services, utilizing cloud computing and big data technologies for traceability and digital healthcare [1]

Core Viewpoint - The company, 弘毅文化集团, has agreed to sell its entire stake in Heartily Health Limited for a total consideration of 1 Hong Kong dollar, which will result in the removal of the subsidiary from the group's consolidated financial statements [1][2] Group 1 - The sale agreement was made between Meerkat Health Holdings Limited, a wholly-owned subsidiary of the company, and Mr. Xu Chun Sheng, the buyer [1] - Heartily Health Limited, the target company, is primarily engaged in investment holding and operates in the pharmaceutical e-commerce and smart healthcare services sectors [1] - Following the completion of the sale on January 30, 2026, the financial performance, assets, and liabilities of the target company will no longer be included in the group's consolidated financial statements [1] Group 2 - The divestment allows the company to optimize its asset allocation and focus on areas with stronger growth potential [2] - By eliminating loss-making operations, the company can reallocate internal resources to support its core businesses in entertainment, media, and digital healthcare services [2] - This strategic move is expected to enhance the overall financial flexibility of the group [2]

Core Viewpoint - The company, 弘毅文化集团, has agreed to sell its entire stake in Heartily Health Limited to Mr. Xu Chun Sheng for a total consideration of 1 Hong Kong dollar, effective January 30, 2026, which will result in the target company no longer being a subsidiary of the group [1]. Group 1: Transaction Details - The seller, Meerkat Health Holdings Limited, is wholly owned by the company and will transfer all issued shares of Heartily Health Limited to the buyer [1]. - The transaction includes the transfer of shareholder loans from the seller to the buyer, with the total consideration being 1 HKD [1]. - Following the completion of the sale, the financial performance, assets, and liabilities of the target company will no longer be included in the group's consolidated financial statements [1]. Group 2: Strategic Implications - The sale allows the group to optimize its asset allocation and focus on areas and businesses with stronger growth potential [2]. - By eliminating loss-making operations, the group can reallocate internal resources to support its existing core businesses in entertainment and media, as well as the development of digital operations in the healthcare industry [2]. - This strategic move is expected to enhance the overall financial flexibility of the group [2].